Saturday 17 October 2026
Export CTSO’s income statement to Excel — free account
Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.11
1.05
+34.31%
Follow CTSO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.59 | 1.07 | 0.95 | 0.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.74) | (8.24) | (30.56) | (40.29) | |
P/B ratio |
6.50 | 6.74 | 16.18 | 0.00 | |
Price to Tangible BV |
11.06 | 14.85 | 0.00 | 0.00 | |
EV/Sales |
1.84 | 1.42 | 1.28 | 0.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.89) | (4.26) | (4.73) | (3.97) | |
EV/FCF |
(6.72) | (4.12) | (4.54) | (3.85) | |
Quick Ratio |
1.48 | 1.42 | 0.73 | 0.47 | |
Current Ratio |
2.11 | 2.13 | 1.09 | 0.66 | |
Net Debt/EBITDA |
(3.10) | (2.78) | (5.11) | (6.48) | |
Debt/Assets |
31.84% | 37.72% | 41.81% | 45.42% | |
Debt/Equity |
1.62 | 2.82 | 7.73 | (22.96) | |
Asset Turnover |
0.79 | 0.81 | 0.81 | 0.87 | |
Operating CF/Net income |
0.81 | 0.88 | 0.23 | 0.13 | |
Capex/Depreciation |
0.09 | (0.46) | (0.07) | 0.01 | |
Interest Coverage |
(4.44) | (5.88) | (3.55) | (3.04) | |
Research and Development Expense of Revenue |
9.68% | 13.45% | 11.56% | 15.08% | |
Selling, General and Administrative Expense of Revenue |
90.77% | 102.19% | 91.93% | 82.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.07 | 0.07 | 0.08 | |
Share Based Compensation of Revenue |
7.81% | 6.86% | 6.14% | 3.82% | |
Graham Net Nets |
(0.26) | (0.44) | (0.58) | (0.98) | |
Graham Number |
0.00 | 0.00 | 0.00 | 5.59 | |
Earnings Yield |
(19.27%) | (20.34%) | (33.57%) | (77.54%) | |
Free Cash Flow Yield |
(17.30%) | (32.17%) | (29.53%) | (40.11%) | |
Revenue per Share |
3.02 | 2.97 | 2.83 | 3.07 | |
Operating CF per Share |
(0.82) | (1.55) | (0.37) | (0.19) | |
Capex per Share |
0.02 | (0.09) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.80) | (1.64) | (0.39) | (0.18) | |
Cash per Share |
2.40 | 2.01 | 1.53 | 1.41 | |
Shareholders Equity per Share |
2.87 | 1.90 | 0.70 | (0.24) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.87 | 1.90 | 0.70 | (0.24) | |
Free Cash Flow |
(2.52) | (5.12) | (1.21) | (0.58) | |
Working Capital |
11.20 | 10.93 | 1.45 | (8.29) | |
Capital Expenditures |
0.06 | (0.29) | (0.05) | 0.01 | |
Net Current Asset Value |
(15.42) | (17.64) | (20.61) | (22.97) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | 0.03 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.03 | 7.44 | 7.41 | 7.26 | |
Average Payables |
2.69 | 3.10 | 3.23 | 2.70 | |
Average Inventory |
3.62 | 4.01 | 3.75 | 3.70 | |
Average Assets |
46.78 | 45.78 | 45.67 | 42.98 | |
Average Common Equity |
11.01 | 8.51 | 8.37 | 5.42 |
Columns are period end dates